Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Genentech to pursue cancer vaccines
by Michael McCoy
September 26, 2016
| A version of this story appeared in
Volume 94, Issue 38
Genentech will pay the German biotech firm BioNTech $310 million in up-front and near-term milestone payments to develop messenger RNA-based individualized cancer vaccines. BioNTech uses next-generation sequencing to identify antigens present in an individual patient’s tumor. The firm then develops mRNA vaccines targeting those antigens. “Unlike any medicine we have ever developed, virtually all cancer patients may potentially benefit from a custom-built cancer vaccine,” says James Sabry, global head of Genentech Partnering.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter